| 重组人血管内皮抑制素联合化疗治疗非小细胞肺癌疗效的Meta分析 |
| 投稿时间：2010-04-02 修订日期：2010-04-02 点此下载全文 |
| 引用本文：张琪,夏爱军.重组人血管内皮抑制素联合化疗治疗非小细胞肺癌疗效的Meta分析[J].药学实践杂志,2010,28(6):451~455 |
| 摘要点击次数: 1407 |
| 全文下载次数: 302 |
|
|
| 中文摘要:目的:评价重组人血管内皮抑制素(恩度)联合化疗方案与单纯化疗治疗非小细胞肺癌疗效。方法:收集20002009年有关恩度联合化疗方案治疗非小细胞肺癌的临床随机对照中文文献,符合纳入标准的共11篇文献,总样本量915例,用RevMan 4.2软件进行Meta分析。结果:恩度联合化疗治疗NSCLC的总有效率OR合并=2.49,(95%CI,1.833.40),疾病控制率OR合并=1.91,(95%CI,1.402.59),P值均小于0.01。结论:本研究在一定程度上反映了在治疗非小细胞肺癌疗效方面,恩度联合化疗方案优于单用化疗组。 |
| 中文关键词:恩度 非小细胞肺癌 Meta分析 |
| |
| Meta-analysis of combining rh-endostatin with chemotherapy in treatment of NSCLC |
|
|
| Abstract:Objective To evaluate the efficacy of combining rh-endostatin with chemotherapy for non-small cell lung cancer(NSCLC) compared with chemotherapy alone.Methods The literature of randomized clinical trials(RCTs) that compared the efficacy of combining rh-endostatin with chemotherapy and chemotherapy alone form 2000 to 2009 were collected.Meta-analysis was employed to evaluate the Results of these therapies by RevMan 4.2.11 literature was seclected including 915 cases.Results Compared with control group,the total OR of efficiency rate of combining rh-endostatin with chemotherapy was 2.49,(95%CI,1.83-3.40),OR of the disease control rate were 1.91,(95%CI,1.40-2.59),both showing significant difference(P<0.01).Conclusion Combining rh-endostatin with chemotherapy was superior to chemotherapy alone in treatment of NSCLC in total efficiency rate and disease control rate. |
| keywords:rh-endostatin NSCLC Meta-analysis |
| 查看全文 查看/发表评论 下载PDF阅读器 |
|
| 关闭 |
|
|
|
